Amgen Inc. closed 19.88% short of its 52-week high of $346.85, which the company reached on July 25th.

Amgen Inc . (NASDAQ:AMGN), a leading biopharmaceutical company with a market capitalization of $149 billion, is navigating a ...

Amgen (AMGN) ended the recent trading session at $277.88, demonstrating a +1.62% swing from the preceding day's closing price. The stock outperformed the S&P 500, which registered a daily gain of 0.53 ...

Amgen's dividend profile shines, but growth slows. See why AMGN stock faces regulatory risks and offers limited incentives ...

Amgen Inc (AMGN) stock saw a modest uptick, ending the day at $272.11 which represents a slight increase of $2.68 or 0.99% from the prior close of $269.43. The stock opened at $276.97 and touched a ...

Wells Fargo sees downside to Amgen’s (AMGN) 2025 consensus estimates, saying the company’ sales guidance could came in below expectations. It ...

Scientists at deCODE genetics/Amgen have constructed a complete map of how human DNA is mixed as it is passed down during reproduction.

Fortune Brands recently announced it will consolidate its U.S offices into one headquarters, taking over two of three office buildings previously owned by Horizon Therapeutics, then Amgen Inc., at ...

Amgen has announced a $1 billion expansion in Holly Springs and has signed a dozen students from Wake Technical Community ...

Amgen Inc. closed $79.75 short of its 52-week high ($346.85), which the company achieved on July 25th.

Amgen’s Lumakras and AstraZeneca’s Calquence are both in line to expand their respective oncology reaches with new FDA ...

Today, Benzinga's options scanner spotted 11 options trades for Amgen. This isn't normal. The overall sentiment of these ...